• Explore /
  • Poster
  • / Ruxolitinib for the prophylaxis of graft-versus-host disease in patients with myelofibrosis receiving hematopoietic stem cell transplantation.

Ruxolitinib for the prophylaxis of graft-versus-host disease in patients with myelofibrosis receiving hematopoietic stem cell transplantation.

Abstract Poster

Authors

null

Tina Yi Jin Hsieh

Beth Israel Deaconess Medical Center, Boston, MA

Tina Yi Jin Hsieh, Gin-Yi Lee, Kevin Sheng-Kai Ma

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care

Sub Track

Toxicity Prevention, Assessment, and Management

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 298)

DOI

10.1200/OP.2023.19.11_suppl.298

Abstract #

298

Poster Bd #

K9

Abstract Disclosures

Similar Posters

First Author: Helen Ajufo

First Author: Joseph Van Galen

First Author: Ruben A. Mesa

First Author: Jan Philipp Bewersdorf